BACKGROUND: Type 2 diabetes has been associated with diminished late-life cognition; less is known about relations of insulin levels and insulin secretion to cognitive change among persons without diabetes. We examined prospectively relations of fasting insulin levels and insulin secretion to cognitive decline among healthy, community-dwelling older men without diabetes. METHODS:Fasting plasma insulin and C-peptide (insulin secretion) levels were measured in 1,353 nondiabetic men, aged 60-92 years (mean = 71.3 years), in the Physicians' Health Study II, who participated in cognitive testing an average of 3.3 years later. Two assessments were administered 2 years apart (range = 1.5-4.0 years) using telephone-based tests (general cognition, verbal memory and category fluency). Primary outcomes were the Telephone Interview for Cognitive Status (TICS), global cognition (averaging all tests) and verbal memory (averaging 4 verbal tests). Multivariable linear regression models were used to estimate the relations of insulin and C-peptide to cognitive decline. RESULTS:Higher fasting insulin was associated with a greater decline on all tests, after adjustment. Findings were statistically significant for the TICS and category fluency, e.g. the multivariable-adjusted mean difference (95% CI) in decline for men with the highest versus lowest insulin levels was -0.62 (-1.15, -0.09) points on the TICS (p for trend = 0.04); this difference was similar to that between men 7 years apart in age. Similarly, there was a greater decline across all tests with increasing C-peptide, but the findings were statistically significant only for the global score (p for trend = 0.03). CONCLUSIONS:Higher fasting insulin and greater insulin secretion in older men may be related to overall cognitive decline, even in the absence of diabetes. 2010 S. Karger AG, Basel.
RCT Entities:
BACKGROUND:Type 2 diabetes has been associated with diminished late-life cognition; less is known about relations of insulin levels and insulin secretion to cognitive change among persons without diabetes. We examined prospectively relations of fasting insulin levels and insulin secretion to cognitive decline among healthy, community-dwelling older men without diabetes. METHODS: Fasting plasma insulin and C-peptide (insulin secretion) levels were measured in 1,353 nondiabetic men, aged 60-92 years (mean = 71.3 years), in the Physicians' Health Study II, who participated in cognitive testing an average of 3.3 years later. Two assessments were administered 2 years apart (range = 1.5-4.0 years) using telephone-based tests (general cognition, verbal memory and category fluency). Primary outcomes were the Telephone Interview for Cognitive Status (TICS), global cognition (averaging all tests) and verbal memory (averaging 4 verbal tests). Multivariable linear regression models were used to estimate the relations of insulin and C-peptide to cognitive decline. RESULTS: Higher fasting insulin was associated with a greater decline on all tests, after adjustment. Findings were statistically significant for the TICS and category fluency, e.g. the multivariable-adjusted mean difference (95% CI) in decline for men with the highest versus lowest insulin levels was -0.62 (-1.15, -0.09) points on the TICS (p for trend = 0.04); this difference was similar to that between men 7 years apart in age. Similarly, there was a greater decline across all tests with increasing C-peptide, but the findings were statistically significant only for the global score (p for trend = 0.03). CONCLUSIONS: Higher fasting insulin and greater insulin secretion in older men may be related to overall cognitive decline, even in the absence of diabetes. 2010 S. Karger AG, Basel.
Authors: Olivia I Okereke; Michael N Pollak; Frank B Hu; Susan E Hankinson; Dennis J Selkoe; Francine Grodstein Journal: Psychoneuroendocrinology Date: 2008-02-07 Impact factor: 4.905
Authors: Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano Journal: JAMA Date: 2008-11-09 Impact factor: 56.272
Authors: Olivia I Okereke; Jae H Kang; Nancy R Cook; J Michael Gaziano; JoAnn E Manson; Julie E Buring; Francine Grodstein Journal: J Am Geriatr Soc Date: 2008-04-01 Impact factor: 5.562
Authors: Marieke van Oijen; Olivia I Okereke; Jae Hee Kang; Michael N Pollak; Frank B Hu; Susan E Hankinson; Francine Grodstein Journal: Neuroepidemiology Date: 2008-04-17 Impact factor: 3.282
Authors: Jeannine S Skinner; Amy Morgan; Hector Hernandez-Saucedo; Angela Hansen; Selena Corbett; Matthew Arbuckle; James Ba Leverenz; Consuelo H Wilkins; Suzanne Craft; Laura D Baker Journal: J Gerontol Geriatr Res Date: 2015-07-23
Authors: Brenna Cholerton; Laura D Baker; Emily H Trittschuh; Paul K Crane; Eric B Larson; Matthew Arbuckle; Hector Hernandez Saucedo; Susan M McCurry; James D Bowen; Wayne C McCormick; Suzanne Craft Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Hye Jeong Yang; Dae Young Kwon; Min Jung Kim; Suna Kang; Na Rang Moon; James W Daily; Sunmin Park Journal: Nutr Metab (Lond) Date: 2015-03-08 Impact factor: 4.169
Authors: Caroline Willmann; Kathrin Brockmann; Robert Wagner; Stephanie Kullmann; Hubert Preissl; Günter Schnauder; Walter Maetzler; Thomas Gasser; Daniela Berg; Gerhard W Eschweiler; Florian Metzger; Andreas J Fallgatter; Hans-Ulrich Häring; Andreas Fritsche; Martin Heni Journal: BMJ Open Diabetes Res Care Date: 2020-11